An overview of recommendations and translational milestones for genomic tests in cancer

[1]  H. Blum,et al.  Clinical Interpretation and Implications of Whole Genome Sequencing , 2014 .

[2]  L. Kux.  OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .

[3]  Lisa McShane,et al.  National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[4]  Anderson.  Translational genomics in cancer research: converting profiles into personalized cancer medicine , 2013 .

[5]  Johanne Tremblay,et al.  Role of genomics on the path to personalized medicine. , 2013, Metabolism: clinical and experimental.

[6]  G. Yousef,et al.  Genomic medicine: new frontiers and new challenges. , 2013, Clinical chemistry.

[7]  E. Drucker,et al.  Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine , 2013, EPMA Journal.

[8]  Geoffrey S Ginsburg,et al.  Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[10]  Ronald L Weiss,et al.  The long and winding regulatory road for laboratory-developed tests. , 2012, American journal of clinical pathology.

[11]  S. Wooding,et al.  The answer is 17 years, what is the question: understanding time lags in translational research , 2011, Journal of the Royal Society of Medicine.

[12]  P. Febbo,et al.  NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  G. Poste.  Bring on the biomarkers , 2011, Nature.

[14]  D G Altman,et al.  Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond , 2009, British Journal of Cancer.

[15]  S. Teutsch,et al.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.

[16]  John P A Ioannidis,et al.  Life Cycle of Translational Research for Medical Interventions , 2008, Science.

[17]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[18]  Richard D Riley,et al.  Primer: an evidence-based approach to prognostic markers , 2005, Nature Clinical Practice Oncology.

[19]  John P A Ioannidis,et al.  Translation of highly promising basic science research into clinical applications. , 2003, The American journal of medicine.

[20]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[21]  G. Hitchings,et al.  ANTAGONISTS OF NUCLEIC ACID DERIVATIVES , 2002 .

[22]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[23]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.

[24]  G. Hitchings,et al.  Antagonists of nucleic acid derivatives. VI. Purines. , 1951, The Journal of biological chemistry.